Edesa Biotech (EDSA) Competitors $2.40 +0.03 (+1.27%) Closing price 03:55 PM EasternExtended Trading$2.40 +0.00 (+0.21%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EDSA vs. UNCY, IZTC, QNTM, IFRX, APLT, ABVC, ICCC, CUE, HOWL, and ADVMShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Unicycive Therapeutics (UNCY), Invizyne Technologies (IZTC), Quantum Biopharma (QNTM), InflaRx (IFRX), Applied Therapeutics (APLT), ABVC BioPharma (ABVC), ImmuCell (ICCC), Cue Biopharma (CUE), Werewolf Therapeutics (HOWL), and Adverum Biotechnologies (ADVM). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Its Competitors Unicycive Therapeutics Invizyne Technologies Quantum Biopharma InflaRx Applied Therapeutics ABVC BioPharma ImmuCell Cue Biopharma Werewolf Therapeutics Adverum Biotechnologies Edesa Biotech (NASDAQ:EDSA) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends. Which has more volatility and risk, EDSA or UNCY? Edesa Biotech has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Do analysts rate EDSA or UNCY? Edesa Biotech currently has a consensus price target of $5.00, suggesting a potential upside of 108.33%. Unicycive Therapeutics has a consensus price target of $60.00, suggesting a potential upside of 1,254.40%. Given Unicycive Therapeutics' higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Edesa Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Do insiders & institutionals hold more shares of EDSA or UNCY? 5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 22.6% of Edesa Biotech shares are owned by insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger earnings and valuation, EDSA or UNCY? Edesa Biotech has higher earnings, but lower revenue than Unicycive Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdesa BiotechN/AN/A-$6.17M-$1.59-1.51Unicycive Therapeutics$680K82.35-$36.73M-$5.10-0.87 Is EDSA or UNCY more profitable? Edesa Biotech's return on equity of -187.01% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edesa BiotechN/A -187.01% -78.72% Unicycive Therapeutics N/A -277.30%-61.53% Does the media prefer EDSA or UNCY? In the previous week, Unicycive Therapeutics had 3 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for Unicycive Therapeutics and 0 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.89 beat Unicycive Therapeutics' score of 0.47 indicating that Edesa Biotech is being referred to more favorably in the media. Company Overall Sentiment Edesa Biotech Very Positive Unicycive Therapeutics Neutral SummaryUnicycive Therapeutics beats Edesa Biotech on 8 of the 14 factors compared between the two stocks. Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.85M$2.91B$5.52B$9.41BDividend YieldN/A2.45%3.80%4.04%P/E Ratio-1.5119.8828.0419.84Price / SalesN/A305.11429.5399.59Price / CashN/A43.1635.8457.94Price / Book3.937.678.125.65Net Income-$6.17M-$55.28M$3.25B$258.00M7 Day Performance14.83%2.50%0.97%2.09%1 Month Performance17.65%11.70%7.36%11.13%1 Year Performance-48.72%4.89%31.31%18.40% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech2.2088 of 5 stars$2.40+1.3%$5.00+108.3%-49.5%$16.64MN/A-1.5120Positive NewsGap UpUNCYUnicycive Therapeutics3.0206 of 5 stars$4.88-2.6%$60.00+1,129.5%+5.9%$61.69MN/A-0.969High Trading VolumeIZTCInvizyne TechnologiesN/A$9.81-2.1%N/AN/A$61.33MN/A0.0029Gap DownQNTMQuantum BiopharmaN/A$21.02+12.5%N/AN/A$61.13MN/A-1.31N/APositive NewsIFRXInflaRx2.791 of 5 stars$0.89+1.4%$6.60+639.9%-45.4%$59.88M$180K-1.0960Gap DownAPLTApplied Therapeutics4.5429 of 5 stars$0.42+1.7%$6.10+1,348.9%-91.7%$59.61M$460K-0.9830Positive NewsABVCABVC BioPharma0.4037 of 5 stars$3.51-11.6%N/A+284.9%$59.60M$510K-27.0030High Trading VolumeICCCImmuCell0.2739 of 5 stars$6.50+0.3%N/A+53.8%$58.76M$26.49M-92.8470CUECue Biopharma3.9243 of 5 stars$0.78+1.4%$3.00+286.1%-6.4%$58.55M$9.29M-1.1660HOWLWerewolf Therapeutics3.8257 of 5 stars$1.29+8.4%$8.33+546.0%-51.4%$57.89M$1.14M-0.7740News CoverageADVMAdverum Biotechnologies4.4165 of 5 stars$2.73+7.5%$23.80+771.8%-67.7%$57.03M$1M-0.43190 Related Companies and Tools Related Companies UNCY Competitors IZTC Competitors QNTM Competitors IFRX Competitors APLT Competitors ABVC Competitors ICCC Competitors CUE Competitors HOWL Competitors ADVM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDSA) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDSA Stock Alerts